Diabetes type 1 is a result of the pancreatic islet beta cells being attacked by the immune system of the human body, and as a result daily insulin injections are needed to manage blood glucose levels. A treatment making use of cord blood stem cells re educates the T cells of a diabetic patient, restarting pancreatic function and decreasing the need to have insulin.
Cord blood stem cells are stem cells derived from cord blood, the blood that remains in a newborn’s umbilical cord following birth.
Lymphocytes that are separated from a diabetic’s blood are gradually passed with Stem Cell Educator therapy across cord blood stem cells immobilized from healthy donors. The re-educated lymphocytes will be returned to the patient after 2 to 3 hours inside the device. After therapy, the patients’ improvement was monitored at 4, 12, 24 and 40 weeks.
C-peptide is a protein fragment created as a byproduct of insulin production and are used to figure out how effectively beta cells are functioning. After 12 weeks following treatment all of the individuals who had been given the therapy experienced improved C -peptide levels. The levels carried on improving at 24 weeks and maintained up until to the finish of the research. This resulted in reducing the daily insulin dosage needed to manage levels of blood glucose. According to these outcomes the HbA1C (glycated hemoglobin) indicator of longterm glucose control also decreased for patients getting the cord blood stem cells therapy.
An improved autoimmune control was also seen. The proportion of regulatory T lymphocytes within the blood was elevated with the Stem Cell Educator therapy. Additional immune function markers, like TGF-beta1 improved as well. The outcomes indicate that it’s this progress in autoimmune management, mediated through the autoimmune regulator AIRE in the cord blood stem cells, enabling the recovery of pancreatic islet beta cells.